Adds Regeneron comment Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen ...

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN) Eylea biosimilar, which UBS analyst Trung ...

BMO Capital says that today’s appeals court decision to affirm the denial of Regeneron’s (REGN) preliminary injunction against Amgen (AMGN) in ...

The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading ...

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Regeneron Pharmaceuticals (NASDAQ:REGN), a leading biotechnology company with a market capitalization of $77 billion, finds itself at a critical juncture as it navigates challenges to its flagship ...

Eylea’s sales in the United States declined 11% year over year to $1.2 billion, primarily due to increased competition. Please note that Regeneron co-developed Eylea with the HealthCare unit of ...

Here's the rundown. Regeneron's issues in the past year are almost entirely related to Eylea, a medicine for wet age-related macular degeneration, which it co-markets with Bayer. The Eylea ...